LB Pharmaceuticals Inc
PublicLB Pharmaceuticals Inc is now publicly traded
The data on this page reflects LB Pharmaceuticals Inc's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 10, 2025
Last Round
Private Placement
Jul 29, 2026
Total Funding Raised
$630.13M
Company Overview
LB Pharmaceuticals Inc is a biopharmaceutical company that develops novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia and bipolar depression.
Sector
Biotech
AI Layer
Non-AI
Keywords
LB Pharmaceuticals Inc Comparables
Compare LB Pharmaceuticals Inc with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eumentis Therapeutics Inc. | 70% | |
| Zhongze Therapeutics | 69% | |
| Kynexis Therapeutics | 66% |
For institutional investors. Book with your work email.
LB Pharmaceuticals Inc Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jul 29, 2026 | ||||
| Private Placement | Feb 5, 2026 | ||||
| IPO | Sep 10, 2025 | ||||
| Series C | Jan 24, 2024 | ||||
| Private Placement | May 3, 2022 | ||||
Series B | Sep 25, 2020 |
For institutional investors. Book with your work email.
LB Pharmaceuticals Inc Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | IPO |
| Janus Henderson Group | Private Placement |
| Balyasny Asset Management L.P. | Private Placement |
| Farallon Capital Management | Private Placement |
| TCG Crossover | Private Placement, Series C |
| Guggenheim Securities | IPO |
| BB Biotech | Private Placement |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 10, 2026
LB Pharmaceuticals, Inc. presents four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress in Germany from Oct 10th-13th '26, covering preclinical and clinical data on LB-102.
- attends_eventOct 10, 2026
LB Pharmaceuticals, Inc. presents four posters on LB-102 and its late-stage clinical development programs at the 39th ECNP Congress in Germany from Oct 10th '26 to Oct 13th '26.
- hiresOct 9, 2026
LB Pharmaceuticals, Inc. appoints Susan G. Kozauer, M.D. as Chief Medical Officer in New York on Sep 15th '26, as the company advances its Phase 3 NOVA-2 schizophrenia trial.
- hiresSep 3, 2026
LB Pharmaceuticals, Inc. appoints Joseph Miller as Chief Financial Officer in New York on Sep 3rd '26, as it prepares for NOVA-2 clinical trial results and the potential commercialization of LB-102.
For institutional investors. Book with your work email.
LB Pharmaceuticals Inc Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.